Company: CDLX
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001666071-25-000046
Chunk: 1

Company: Cardlytics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 1
---
 to receive your Annual Meeting materials by mail, the Notice of Annual Meeting of Stockholders, Proxy Statement, 2024 Annual Report and proxy card will be enclosed. If you receive your proxy materials via email, the email will contain voting instructions and links to the Annual Report and Proxy Statement on the Internet, both of which are available at www.proxyvote.com.

Details regarding admission to the Annual Meeting and the business to be conducted at the Annual Meeting are described in the accompanying Notice of Annual Meeting of Stockholders and Proxy Statement. Whether or not you plan to attend the meeting, your vote is very important, and we encourage you to vote promptly. You may vote by either marking, signing and returning a proxy card or using telephone or Internet voting. For specific instructions on voting, please refer to the instructions on your proxy card.

We look forward to seeing you at the Annual Meeting.

Sincerely,

| Amit Gupta              |
| Chief Executive Officer |

<div align='center'>2</div>

#### CARDLYTICS, INC.

#### 675 Ponce de Leon Ave. NE, Suite 4100

#### Atlanta, Georgia 30308

### NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

#### To Be Held On May 20, 2025
Dear Stockholder:

The Annual Meeting of Stockholders (the "Annual Meeting") of Cardlytics, Inc. (the "Company") will be held at the offices of the Company at 675 Ponce de Leon Ave. NE, Suite 4100, Atlanta, GA 30308, on Tuesday, May 20, 2025 at 2:00 p.m. Eastern Time for the following purposes:

1. To elect the Board of Directors' three nominees for Class I director, Jon Francis, Scott Hill and Alex Mishurov, each to hold office until the 2028 Annual Meeting of Stockholders.

2. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm, or auditors, for the fiscal year ending December 31, 2025.

3. To approve the Company's 2025 Equity Incentive Plan in the form attached as Appendix B to the Proxy Statement.

4. To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.

5. To conduct any other business properly brought before the meeting.

These items of business are more fully described in the Proxy Statement accompanying